Is Two Too Few? Denosumab Advisory Cmte. Lacked Permanent Members
Executive Summary
The Reproductive Health Drugs Advisory Committee reviewing Amgen's Prolia (densoumab) had the fewest permanent members on the panel it has had in the last five years